Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm glad you enjoyed it too, BR. It certainly cracked up all of my nurses.
I also managed to blurt out a couple of my best off-color barnyard animal jokes in the OR as they were putting me under.
Thanks, Ganz. I tried to turn a serious situation into as much of a comedy show as I could muster. I hope Moose will share it with his bride.....but only after she has been cleared to laugh.
I realize that, OB. I'm just trying to save you all future aggravation and heartache. Life is too short. Move in to something that actually has a cutting edge product or service to provide. There are tons of them out there.
I would love that opportunity, Cosa, but I think the street finally is starting to wise up a bit. My floor is at 15.30
I'll be brief. I had a pacemaker installed on June 23rd. Having been a jock all my life, I couldn't figure out why I was winded running on my Florida Panhandle Gulf Coast at sea level. Anyway...it cost me 2 1/2 days of work, and now I'm back to running/walking 3-4 miles on demand...usually in the evening. I haven't been at this much peace for many years. True priorities, all of a sudden, come into the picture, and not much else matters. Here's a couple of funny tidbits: I was wide awake and alert after the one hour procedure. My nurse asked me if I wanted to watch television on the one channel. It was The Learning Channel. What was on? Open Heart Surgery. I had the best time reminding all of my nurses on all three shifts that not one of them knew the difference between an oral and rectal thermometer until I told them. That difference, of course, is "the taste".
What Moose reminds us about is a necessary wake-up call to get checked-up so we won't have to check-out at our first opportunity. I too am elated that she is on the mend and am also elated that Moose is enamored with the quality of care she has received. Onward and upward. I also have been blessed recently with extraordinary medical care.
You all continue to grasp blindly for that ever-elusive straw once known as Medizone. I see no reason why this stock shouldn't eventually be shut down and am scratching my head as to why it continues to trade. There really is nothing here.
LLY, GLX, and PFE, IMHO, based on prior research, are my three best candidates. LLY has failed twice, GLX has a vastly inferior product, and PFE was reported to have an interest. A bidding war would be perfect. We're getting ready to turn over 15% to 20% of the outstanding shares just this week.
Your main concerns should be why a new domain owner would support a group of shareholders of a liquidated company with no possibility of bringing any type of product or service to market. The hammer should fall at anytime via the regulatory bodies involved.
We're again approaching 6 1/2 million shares in volume. Sell-offs again have been negligible....unlike the past six months. We're at the highs of the day as the market continues to move lower. Short-covering, someone like the Reddit gang, and maybe a potential suitor are at work here today.
We touched 16.90 today and closed with a volume just shy of 6 1/2 million shares. Little by little we're working our way back from the February levels right after approval. We reached $20.50 without any sales back then. Onward and upward. The Rheumatologist article was enlightening as to how the process works.
Last week, I missed a write-up on Aurinia from the Motley Fool crew. It actually put the company on a pedestal and called it a stock to own for early retirement. It's one of the most positive articles I have ever seen on the company. So....it looks like the MF gang thinks it's going a lot higher.
old, old news
Breaking 16.20, closing above 16, and then sell-offs into the 14s would be a great sign. Chartists would look at the recent lows going from the 10s to the 12s as being significant. Higher lows. We're getting there.
So...with a Chapter 7 liquidation bankruptcy completed and all rights to the old Ascepticsure technology sold "for a song" to a completely unrelated entity.....some of you think the new domain owner is going to recognize and support the old Medizone shareholders. Riiiiiiiiiiigggggggghhhhhhttt!
For what it's worth, the Mayo Clinic investment account sold half its position in SRNE.
Well....the fear of Covid might be at work again...hampering 3rd quarter revenues. Whatever the cause, another buying opportunity will present itself when AUPH reaches the 12s.
Aptose appears to be in an enviable spot. Yes, it is still in the Phase I/II, but what I have read tells me it's for the right reasons. Safety and efficacy are being achieved at multiple dosage levels. How many times does that happen throughout biotech history? Somebody on here please tell me how incorrect I am....if I am incorrect at all. The company also announced, albeit a few months ago, a complete remission with an acute leukemia patient. Again....somebody tell me I am barking up the wrong tree and why.
Well.....one has to ask oneself some obvious questions. Why no sales to existing customers? That fact alone will thwart any effort to start a human clinical trial. Where will the much needed global stats emerge to offer efficacy results to support that clinical trial? The company doesn't have a lot of options. Merck continues to offer its vaccine for this indication. Another reverse split? Why bother? This thing is headed to the pinks and then OUT without the prospect for approval in the developed world.
August 15 call expirations should be fun to watch next week. What's interesting this week is that selling is being met with buying...unlike previous trading sell-offs.
A nice day amid the late session profit taking. I can assume a scared short coverer bought the stock at $16.20 this morning.
Yesterday's earnings commentary vaguely alluded to Covid related issues hampering the launch. Going from nearly -0- sales in the first quarter (when there was less than two months to produce sales) to over 6 million in the second quarter tells me initial acceptance has been solid, more infrastructure has been created, and growth could become exponential from here. One of the subscription hawking companies mentioned Pfizer yesterday as an example of a good fit for Aurinia.
Pardon my intrusion. Am I looking at a company with zero products in the pipeline and three employees? My goodness....the market must be at a frothy top.
I am a bit miffed at Zack's obvious lack of understanding of biotech. I think it has a universal company analysis form that it uses regardless of the industry it covers. Analysts have forgotten that this product was not approved until late January. Product launches/rollouts are the penultimate results of successful FDA product reviews. No launch is inexpensive, and no launch happens overnight. We're four months, at best, into this process.
This share exchange today is quite impressive and tells me that a combination of short covering plus the entry of the anti-short groups might be at work here. The company has done a good job in the past of keeping secrets secret....no leaks.
The hedge funds have been active here for a while. It will be an ugly short-covering period for them at some point.
I took a look around the net this morning and checked analyst coverage and ratings. I came up with nine current ratings: 8 buys and 1 hold. My guess is hedge funds are betting that 2nd quarter revs are going to be below expectations. Should they be wrong, however, we could see quite a blast-off from these levels.
The problem with hedge funds is that they could be on either side of the transaction. My short-term gut feeling right now is that institutions are not banking on revenues for the second quarter.
Yep, Jess.....this entry of AstraZeneca merely gives Aurinia one more potential suitor in the "big-boy" category.
Aurinia rather quietly hired a new member for the management team. This lady has a bunch of M & A experience, and, I'll bet, a bunch of the right connections. Worth checking out.
Today was a solid, backing and filling, positive result on over 3 million shares
I could speculate that the big three; Boehringer, Lilly, and Glaxo, already own shares of Aurinia.....just not enough (yet) to raise any regulatory eyebrows.
Boehringer Ingelheim, Lilly (twice), La Jolla, and others have not been able to create a viable LN product. The world is starting to find out that the Glaxo product is an also-ran, at best. I say let the bidding war begin! Maybe it began today.
We have an 80 cent rise this morning on solid volume (2.6 million) with little resistance. Pure speculation would tell me that individual investors are starting to double down (or up), and there is some institutional play here as well. Maybe a competitor?
Oh my.....these unseasoned amateur analysts. When did this product obtain approval? Late January 2021. So there goes the first month out of the quarter. Do we really think the company had more than 1/2 a quarter to make anything happen? The CIGNA coverage and Medicare coverage are major milestones, and more insurance companies in the private sector will follow suit. Reimbursement is half the battle. Every else is falling into place, and now we have a little merger speculation on top of it.
What does the "Q" stand for in the symbol, everyone?
It's okay. The groundwork continues to be laid. Today's trading may be little else than some profit taking by speculators who bought it in the elevens over the past few weeks.
The company just leaped over one of the most serious hurdles: insurance coverage. ICER is on the planet, in part, to give insurance companies reasons to NOT cover new drugs. CIGNA, obviously, is not playing politics and recognizes VOC as the coming SOC. One could think that other major insurers will follow suit.
Oh my. People associated with this IHUB board for many years have tried to tell you all that there is nothing going on with Medizone. Chapter 7 took place, the company was liquidated, and the once promising ozone cleansing technology was sold to another entity. Whoever takes over this "shell" will be a different company with a different agenda and a different product or service. I am not sure shy the NASD hasn't overseen the demise of MZEIQ's trading capabilities.
The biotech universe has been out of favor for a couple of months. The NBI peaked at 5466 in February and now stands in the mid-4800s. Several companies have failed various tests with the FDA. So the atmosphere is far from complacent like it was just a few months ago. The "Deep Value" sector has taken over the markets for the time being. So we just have to remain diligent and patient. The volume, when AUPH was falling, was never high enough to bother me. The recent upside volume has been a bit more supportive.